The GSK3B Knockout DLD-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human DLD-1 colorectal adenocarcinoma cell line. This product provides a pooled population of cells with targeted disruption of the GSK3B gene, enabling loss-of-function studies without clonal selection. The polyclonal format preserves heterogeneous genetic backgrounds and is suitable for experiments where a mixed knockout population appropriately models biological variability.
The DLD-1 parental cell line originates from a colorectal adenocarcinoma and retains key characteristics of colon epithelium, including absorptive and barrier functions. As an adherent epithelial line with stable growth properties, DLD-1 cells are widely employed to study colon cancer biology, drug responses, and signal transduction. Their genetic profile includes mutations in APC and other Wnt pathway components, making them a relevant context for investigating GSK3B function.
GSK3B (Glycogen Synthase Kinase 3 Beta) is a serine/threonine kinase central to multiple signaling cascades. In the canonical Wnt/beta-catenin pathway, GSK3B functions within a destruction complex comprising Axin, APC, and beta-catenin. It phosphorylates beta-catenin, targeting it for ubiquitin-mediated proteasomal degradation. Upon Wnt ligand binding to Frizzled and LRP5/6 receptors, Dishevelled is activated, leading to inhibition of GSK3B and stabilization of beta-catenin. Stabilized beta-catenin translocates to the nucleus, where it associates with TCF/LEF transcription factors to drive expression of targets such as c-Myc and cyclin D1. GSK3B is also modulated by insulin/PI3K/AKT signaling, where AKT-mediated phosphorylation at Ser9 inhibits its activity, and it interacts with FRAT1. Downstream targets include NFAT, and its activity influences cell proliferation, differentiation, and metabolism.
In the DLD-1 background, GSK3B knockout is particularly informative for colorectal cancer research. DLD-1 cells harbor APC truncations that impair beta-catenin degradation; however, residual GSK3B function may still regulate beta-catenin turnover or interact with alternative pathways. Disrupting GSK3B can potentiate Wnt signaling, providing a model to dissect beta-catenin-dependent and -independent roles. This polyclonal knockout population enables investigation of genetic interactions, drug sensitivity, and the consequences of complete GSK3B loss in a cancer-relevant epithelial context.
Researchers can employ this model for Wnt pathway dissection using TOP/FOP flash reporter assays to measure beta-catenin transcriptional activity, western blotting to assess beta-catenin protein levels, and immunofluorescence to examine its subcellular localization. Cell proliferation assays can reveal functional outcomes of GSK3B disruption. Additionally, the cells serve in drug target validation and screening for modulators of Wnt signaling. For further details and ordering information, contact Ascent Research.
